Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanespimycin in Refractory Metastatic Breast Cancer
NCT00096109Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanespimycin in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Response Rate (Complete Response + Partial Response) up to 7 years, Progression Free Survival up to 7 years and 1 more. Started Sep 2005; status: terminated.
02
Drugs
tanespimycin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00096109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096109.